ID   LIM6-TR
AC   CVCL_B6NT
SY   LIM6-TRAIL Resistant
DR   cancercelllines; CVCL_B6NT
DR   Wikidata; Q112929998
RX   PubMed=21941373;
CC   Population: Caucasian.
CC   Characteristics: Has high liver-metastasizing ability during cecal growth (from parent cell line).
CC   Selected for resistance to: UniProtKB; P50591; Human TNFSF10/CD253.
CC   Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Phe (c.134C>T); ClinVar=VCV000017588; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: In situ; Colon; UBERON=UBERON_0001155.
CC   Cell type: Epithelial cell of colon; CL=CL_0011108.
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_D240 ! LiM6
SX   Female
AG   58Y
CA   Cancer cell line
DT   Created: 17-03-22; Last updated: 05-10-23; Version: 5
//
RX   PubMed=21941373; DOI=10.1038/cdd.2011.123;
RA   Mazurek N., Byrd J.C., Sun Y., Hafley M., Ramirez K., Burks J.,
RA   Bresalier R.S.;
RT   "Cell-surface galectin-3 confers resistance to TRAIL by impeding
RT   trafficking of death receptors in metastatic colon adenocarcinoma
RT   cells.";
RL   Cell Death Differ. 19:523-533(2012).
//